Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer

被引:7
|
作者
Luo, Lixi [1 ]
Wei, Qun [1 ]
Xu, Chenpu [1 ]
Dong, Minjun [1 ]
Zhao, Wenhe [1 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Sch Med, Hangzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
pyroptosis; tumor microenvironment; triple-negative breast cancer; prognosis; immune checkpoints; TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE INSTABILITY; DOUBLE-BLIND; T-CELLS; IMMUNOTHERAPY; PHENOTYPE;
D O I
10.3389/fimmu.2022.933703
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The survival outcome of triple-negative breast cancer (TNBC) remains poor, with difficulties still existing in prognosis assessment and patient stratification. Pyroptosis, a newly discovered form of programmed cell death, is involved in cancer pathogenesis and progression. The role of pyroptosis in the tumor microenvironment (TME) of TNBC has not been fully elucidated. In this study, we disclosed global alterations in 58 pyroptosis-related genes at somatic mutation and transcriptional levels in TNBC samples collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. Based on the expression patterns of genes related to pyroptosis, we identified two molecular subtypes that harbored different TME characteristics and survival outcomes. Then, based on differentially expressed genes between two subtypes, we established a 12-gene score with robust efficacy in predicting short- and long-term overall survival of TNBC. Patients at low risk exhibited a significantly better prognosis, more antitumor immune cell infiltration, and higher expression of immune checkpoints including PD-1, PD-L1, CTLA-4, and LAG3. The comprehensive analysis of the immune landscape in TNBC indicated that alterations in pyroptosis-related genes were closely related to the formation of the immune microenvironment and the intensity of the anticancer response. The 12-gene score provided new information on the risk stratification and immunotherapy strategy for highly heterogeneous patients with TNBC.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer
    Li, Xiao-Fen
    Fu, Wen-Fen
    Zhang, Jie
    Song, Chuan-Gui
    BMC CANCER, 2022, 22 (01)
  • [22] An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer
    Xiao-Fen Li
    Wen-Fen Fu
    Jie Zhang
    Chuan-Gui Song
    BMC Cancer, 22
  • [23] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2011, 16 : 71 - 78
  • [24] Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer
    Jeon, Hyae Min
    Kim, Do Hee
    Jung, Woo-Hee
    Koo, Ja Seung
    TUMORI JOURNAL, 2013, 99 (04): : 555 - 564
  • [25] Uncovering the molecular subtypes of triple-negative breast cancer with a noninvasive radiomic methodology
    Su, Guan-Hua
    Xiao, Yi
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CELL REPORTS MEDICINE, 2022, 3 (12)
  • [26] Developing therapies for triple-negative breast cancer subtypes
    Okines, Alicia
    Turner, Nicholas
    LANCET ONCOLOGY, 2024, 25 (02): : 149 - 151
  • [27] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2010, 15 : 49 - 56
  • [28] Incidence and histological subtypes of triple-negative breast cancer
    Marian, C.
    Boros, M.
    Podeanu, M. D.
    Stolnicu, S.
    VIRCHOWS ARCHIV, 2011, 459 : S84 - S84
  • [29] Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer
    Liu, Cun
    Li, Ye
    Xing, Xiaoming
    Zhuang, Jing
    Wang, Jigang
    Wang, Chunyan
    Zhang, Lujun
    Liu, Lijuan
    Feng, Fubin
    Li, Huayao
    Gao, Chundi
    Yu, Yang
    Liu, Jingyang
    Sun, Changgang
    MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 28 : 670 - 684
  • [30] Triple-negative breast Cancer risk: Ancestry and immune response.
    Ford, Marvella E.
    Brown, Erika T.
    Turner, David P.
    Findlay, Victoria J.
    Esnaola, Nestor F.
    Alberg, Anthony J.
    Bolick, Susan
    Hurley, Deborah
    Kramer, Rita
    Salley, Judith D.
    Cunningham, Joan E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 66 - 66